MPWT
GLUE icon

MassMutual Private Wealth & Trust’s Monte Rosa Therapeutics GLUE Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-103
Closed -$1.69K – 2438
2026
Q1 		$1.69K Buy
+103
New +$1.97K ﹤0.01% 2013

Other funds holding GLUE

Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MassMutual Private Wealth & Trust's GLUE Position: Q2 2026 in Review

MassMutual Private Wealth & Trust sold out of Monte Rosa Therapeutics (GLUE) in Q2 2026, closing a stake of 103 shares — an estimated $1.69K sold.

MassMutual Private Wealth & Trust first reported a position in GLUE in Q1 2026 and held it in 1 quarter. The position peaked at $1.69K in Q1 2026. 40 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • MassMutual Private Wealth & Trust reported no remaining Monte Rosa Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 103 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.69K.
  • MassMutual Private Wealth & Trust first reported a position in Monte Rosa Therapeutics in Q1 2026 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Monte Rosa Therapeutics position peaked at $1.69K in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on MassMutual Private Wealth & Trust's 13F filing for Q2 2026, filed 2 Jul 2026.